Jiangsu Recbio Technology Co Ltd
02179
Company Profile
Business description
Jiangsu Recbio Technology Co Ltd is a vaccine company dedicated to the development and commercialization of safer and more effective vaccines to address the far-unmet public needs. Hygiene needs. The company focuses on the R&D of HPV vaccine candidates. The company's vaccine portfolio currently consists of 12 vaccines, including three strategic products, namely REC603, a recombinant HPV 9-valent vaccine under phase III clinical trial.
Contact
No. 888 Yaocheng Avenue
Medical High-tech District
Jiangsu Province
Taizhou
CHNT: +86 52388820888
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
507
Stocks News & Analysis
stocks
Chart of the Week: Inflation fears dampen sentiment on retailers
Rising inflation is the fly in the ointment.
stocks
Here’s 3 Top Rated ASX shares for 2026
As we start the new year, let’s take a closer look at three compelling opportunities on the ASX
stocks
Undervalued Aussie e-commerce winner
Shares attractive due to near term profit margin increase and structural growth.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,046.50 | 22.30 | 0.25% |
| CAC 40 | 8,224.41 | 9.51 | -0.12% |
| DAX 40 | 25,151.76 | 29.50 | 0.12% |
| Dow JONES (US) | 48,996.08 | 466.00 | -0.94% |
| FTSE 100 | 10,033.28 | 14.93 | -0.15% |
| HKSE | 26,149.31 | 309.64 | -1.17% |
| NASDAQ | 23,584.28 | 37.10 | 0.16% |
| Nikkei 225 | 51,117.26 | 844.72 | -1.63% |
| NZX 50 Index | 13,716.86 | 1.84 | 0.01% |
| S&P 500 | 6,920.93 | 23.89 | -0.34% |
| S&P/ASX 200 | 8,720.80 | 18.20 | 0.21% |
| SSE Composite Index | 4,082.98 | 2.79 | -0.07% |